- Home
- TAYD vs NERV Comparison
TAYD vs NERV Comparison
Compare TAYD & NERV Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | TAYD | NERV |
|---|---|---|
| Founded | 1955 | 2007 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 234.0M | 269.6M |
| IPO Year | 1995 | 2014 |
Fundamental Metrics
Financial Performance| Metric | TAYD | NERV |
|---|---|---|
| Price | $88.83 | $6.77 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 1 |
| Target Price | ★ $70.00 | $4.00 |
| AVG Volume (30 Days) | 46.8K | ★ 111.4K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | 11.24 | ★ 104.12 |
| EPS | ★ 2.87 | N/A |
| Revenue | ★ $46,292,725.00 | $41,175,600.00 |
| Revenue This Year | $10.61 | N/A |
| Revenue Next Year | $8.56 | N/A |
| P/E Ratio | $30.33 | ★ N/A |
| Revenue Growth | ★ 3.84 | N/A |
| 52 Week Low | $29.50 | $1.15 |
| 52 Week High | $90.37 | $12.46 |
Technical Indicators
Market Signals| Indicator | TAYD | NERV |
|---|---|---|
| Relative Strength Index (RSI) | 64.29 | 70.20 |
| Support Level | $43.76 | $1.70 |
| Resistance Level | N/A | $12.46 |
| Average True Range (ATR) | 5.01 | 0.49 |
| MACD | -0.24 | 0.01 |
| Stochastic Oscillator | 90.45 | 69.93 |
Price Performance
Historical ComparisonAbout TAYD Taylor Devices Inc.
Taylor Devices Inc is involved in the design, development, manufacture, and marketing of shock absorption, rate control, and energy storage devices for use in various types of machinery, equipment, and structures. The company's product line includes Seismic dampers, Fluidicshoks, Crane and industrial buffers, Self-adjusting shock absorbers, Liquid die springs, and Vibration Dampers. Its products are generally used to absorb, control, or mitigate the motion of masses caused by earthquakes or explosions. The company markets its products to various industries such as industrial, steel mills, buildings, bridges, aerospace, defense, and automotive industries.
About NERV Minerva Neurosciences Inc
Minerva Neurosciences Inc is a clinical-stage biopharmaceutical company. It focuses on the development and commercialization of a portfolio of product candidates to treat patients suffering from central nervous system diseases. The company's pipeline products include MIN-101, MIN-202, and MIN-301. Targeted disorders include schizophrenia, insomnia, depressive disorder, and Parkinson's disease. Its product portfolio and potential indications include Roluperidone for the treatment of negative symptoms in patients with schizophrenia; Seltorexant, for the treatment of insomnia disorder and depressive disorder; MIN-117 for the treatment of MDD; and MIN-301 for the treatment of Parkinson's disease.